Natco Pharma Ltd

BSE: 524816

45

total announcements

NATCOPHARM.NS · 15 min delayed

Key Stats · Yahoo Finance · as of 19 Nov 2026

Market Cap

₹16,098 Cr

P/E (TTM)

17.9

P/E (Forward)

17.5

EPS (TTM)

₹45.89

52W Low

₹773.60

52W High

₹1,226.80

Dividend Yield

0.54%

Beta

0.18

Price / Book

1.5

Return on Equity

9.01%

Debt / Equity

10.6

Revenue (TTM)

₹3,092 Cr

Gross Margin

78.56%

Operating Margin

18.32%

BSECompany UpdateResults14h ago

Natco Pharma Ltd

Q2FY27 Earnings Conference Call Transcript

Natco Pharma Ltd's Q2FY27 earnings conference call transcript has been released, showing a 28.4% increase in consolidated total revenues to ₹1,019.4 crores, driven by strong performance in international formulation business. EBITDA including other income stood at ₹310 crores, with EBITDA margin of 30.4%. Consolidated profit after tax was ₹202.6 crores. The company acquired an additional 13.25% stake in associate company Adcock Ingram Holding Limited, taking its total holdings to 49%. Domestic formulation business revenue stood at ₹145 crores, with Brazil business revenue growing 66%.

Read more →📎 1 attachment
BSECompany UpdateMgmt Change2d ago

Natco Pharma Ltd

Intimation of Investor Meet

Natco Pharma Ltd has announced an investor meet on November 19, 2026, in Pune, where company officials will interact with investors. The meeting schedule is subject to change due to exigencies. No unpublished price-sensitive information will be discussed during the interactions.

Read more →📎 1 attachment
BSEResult▲ PositiveResults5d ago

Natco Pharma Ltd

Un audited Financial Results for the quarter and half year ended 30th September, 2026

Natco Pharma Ltd has announced unaudited financial results for the quarter and half year ended September 30, 2026, with a profit before tax of Rs. 2,432 crore and a profit for the period of Rs. 2,026 crore. The company has also declared a second interim dividend of Rs. 1.25 per equity share. The results show a decline in profit before tax and profit for the period compared to the same period last year.

Read more →📎 1 attachment
BSEBoard Meeting▲ PositiveResults5d ago

Natco Pharma Ltd

Outcome of Board Meeting

Natco Pharma Ltd has announced unaudited financial results for the quarter and half year ended September 30, 2026, along with the declaration of a second interim dividend of Rs. 1.25 per equity share. The company has also provided a consolidated balance sheet as of September 30, 2026.

Read more →📎 1 attachment
BSEInsider Trading / SASTResults30 Oct 2026

Natco Pharma Ltd

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Venkaiah Chowdary Nannapaneni

Natco Pharma Ltd has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, regarding the allotment of equity shares through a rights issue to eligible equity shareholders. The disclosure includes details of the promoters and members of the promoter group who have acquired shares through the allotment.

Read more →📎 1 attachment
BSEBoard MeetingResults29 Oct 2026

Natco Pharma Ltd

Natco Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2026 ,inter alia, to consider and approve the Un-audited Financial Results for the Quarter ended 30th September, 2026 and declaration of Second Interim Dividend, if any

Natco Pharma Ltd has scheduled a Board Meeting on 13/11/2026 to consider unaudited financial results for Q2 FY 2026-27 and declare second interim dividend, if any.

Read more →📎 1 attachment
BSEInsider Trading / SAST22 Oct 2026

Natco Pharma Ltd

Update on Trading Window Closure period

Natco Pharma Ltd has closed its trading window for all directors, designated persons, and connected individuals from October 1, 2026, until 48 hours after the declaration of unaudited financial results for the quarter ended September 30, 2026. The trading window will reopen from October 23, 2026, to October 28, 2026, to enable the credit of rights equity shares in demat accounts of allottees.

Read more →📎 1 attachment
BSECompany UpdateRegulatory16 Oct 2026

Natco Pharma Ltd

Compliance Certificate under Reg.74(5) of SEBI(DP) Regulations, 2018

Natco Pharma Ltd has issued a compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026, confirming the dematerialization of securities and updating the records of the company.

Read more →📎 1 attachment
BSECompany UpdateFundraise7 Oct 2026

Natco Pharma Ltd

News Paper Publications

Natco Pharma Ltd has published newspaper notices regarding its forthcoming Rights Issue in Financial Express, Surya, and Janasatta on October 7, 2026, as per Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Read more →📎 1 attachment
BSEAGM/EGMMgmt Change30 Sept 2026

Natco Pharma Ltd

Evoting Results along with Scrutinizer Report for the 43rd Annual General Meeting held on 30/09/2026

Natco Pharma Ltd has announced the voting results of its 43rd Annual General Meeting, with all resolutions passed with high voting percentages. The company has also announced the re-appointment of a director and the ratification of the remuneration of cost auditors. Additionally, the company has sought shareholder approval for raising funds up to Rs. 2,000 crores through various means.

Read more →📎 1 attachment
BSEInsider Trading / SASTMgmt Change30 Sept 2026

Natco Pharma Ltd

Closure of Trading Window

Natco Pharma Ltd has announced the closure of its trading window for directors, designated persons, and their relatives from October 1, 2026, until 48 hours after the declaration of unaudited financial results for the quarter ending September 30, 2026.

Read more →📎 1 attachment
BSEAGM/EGMResults30 Sept 2026

Natco Pharma Ltd

Proceedings of the 43rd Annual General Meting

Natco Pharma Ltd held its 43rd Annual General Meeting on September 30, 2026, through video conference. The meeting was attended by 51 members, and the company's Chairman and Managing Director, V.C. Nannapaneni, conducted the proceedings. The meeting approved the audited annual financial statements for FY 2025-26, confirmed three interim dividends, and re-appointed a director. The company also announced plans to raise up to ₹2,000 crores through various methods.

Read more →📎 1 attachment
Page 1 of 3Next →